About US
Contact us
-
Shionogi quests to slay antibiotic resistance with cefiderocol licensing and collaboration troikaShionogi is teaming up with the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI) in a bid to boost antibiotic access worldwide.2022/6/14
-
Pfizer already agreed to delay supply of COVID-19 shots to EU, now the bloc wants moreLast month, in response to a decrease in demand, Pfizer and its COVID-19 vaccine partner BioNTechagreedto delay supplies of their shot to the European Union. Jabs due to be shipped from June to Augus2022/6/14
-
Biogen, Alectos collaborate to develop Parkinson’s disease treatmentBiogen hasenteredinto a license and collaboration agreement with Alectos Therapeutics to develop and commercialise AL01811 for the treatment of Parkinson’s Disease (PD). AL01811 is a new preclinical2022/6/10
-
Sinovac Biotech receives WHO prequalification for polio vaccineChina’s Sinovac Biotech has receivedprequalificationfrom the World Health Organization (WHO) for its Poliomyelitis Vaccine (Vero Cell, Inactivated Sabin strains) (sIPV). With the latest development,2022/6/10
-
ADA: 'Impressed and pleased,' Boehringer trumpets latest Jardiance win at ADAJardiance partners Eli Lilly and Boehringer Ingelheim have worked hard to establish their medicine as a competitive force in the diabetes and cardiovascular treatment landscapes. Now, they're rolling2022/6/7
-
ASCO: Merck exec on his first ASCO, Keytruda's journey and new dataNew data presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting reaffirm Keytruda’s potentialagainst stage 2 skin cancer, an exec said. In an interview, he reflected on his2022/6/7
-
FDA approves Novartis’ cell therapy for follicular lymphoma in adultsNovartis has obtained acceleratedapprovalfrom the US Food and Drug Administration (FDA) for its CAR-T cell therapy Kymriah (tisagenlecleucel) to treat adults with relapsed or refractory (r/r) follicu2022/6/2
-
China grants approval for GSK’s two-dose HPV vaccine for girlsChina’s National Medical Products Administration (NMPA) has grantedapprovalfor GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between the age of nine to 14 years to prevent cer2022/6/2
-
China grants approval for GSK’s two-dose HPV vaccine for girlsChina’s National Medical Products Administration (NMPA) has grantedapprovalfor GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between the age of nine to 14 years to prevent cer2022/5/31
-
FDA approves Novartis’ cell therapy for follicular lymphoma in adultsNovartis has obtained acceleratedapprovalfrom the US Food and Drug Administration (FDA) for its CAR-T cell therapy Kymriah (tisagenlecleucel) to treat adults with relapsed or refractory (r/r) follicu2022/5/31